Amelioration of arthritis in two murine models using antibodies to oncostatin M - PubMed (original) (raw)
Amelioration of arthritis in two murine models using antibodies to oncostatin M
C Plater-Zyberk et al. Arthritis Rheum. 2001 Nov.
Free article
Abstract
Objective: Oncostatin M (OSM) is a member of the interleukin-6 cytokine family, with well-documented effects on cell growth and differentiation. OSM also has proinflammatory and cartilage degradative properties. The aim of this study was to investigate the significance of OSM in arthritis pathology using a neutralizing antibody in arthritis models.
Methods: Collagen-induced arthritis (CIA) was established in male DBA/1 mice. Reverse transcriptase-polymerase chain reaction was used to detect OSM messenger RNA (mRNA) message levels in arthritic joints. Neutralizing anti-OSM antibody or control immunoglobulin was administered on days 1 and 3 after disease onset. Animals were assessed for clinical arthritis for 2 weeks, followed by a histologic analysis of paws. Pristane-induced arthritis (PIA) was produced in male CBA mice dosed with anti-OSM or control immunoglobulin immediately before disease onset. Mice with PIA were assessed for clinical arthritis over a period of 100 days.
Results: Levels of mRNA for OSM, but not GAPDH, were elevated in arthritic joints of mice with CIA compared with those of normal controls. Mice with CIA treated with anti-OSM antibody showed significant amelioration of both the clinical severity (P < 0.01) and the number of affected paws (P < 0.01) compared with control animals. Histologic analysis confirmed these clinical findings, revealing a marked reduction in cellular infiltration of synovium and cartilage damage. In the PIA model, the incidence of arthritis was 65% in the control group compared with 0% in the anti-OSM-treated animals.
Conclusion: These results demonstrate a key role for endogenously produced OSM as a potent mediator of joint pathology, and suggest that OSM might be a potentially important, novel therapeutic target for treatment of established rheumatoid arthritis.
Similar articles
- Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegård D, van den Berg WB. Joosten LA, et al. Arthritis Res. 1999;1(1):81-91. doi: 10.1186/ar14. Epub 1999 Oct 26. Arthritis Res. 1999. PMID: 11056663 Free PMC article. - Growth plate damage, a feature of juvenile idiopathic arthritis, can be induced by adenoviral gene transfer of oncostatin M: a comparative study in gene-deficient mice.
de Hooge AS, van de Loo FA, Bennink MB, Arntz OJ, Fiselier TJ, Franssen MJ, Joosten LA, Van Lent PL, Richards CD, van den Berg WB. de Hooge AS, et al. Arthritis Rheum. 2003 Jun;48(6):1750-61. doi: 10.1002/art.10972. Arthritis Rheum. 2003. PMID: 12794844 - Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB. Lubberts E, et al. Arthritis Rheum. 2004 Feb;50(2):650-9. doi: 10.1002/art.20001. Arthritis Rheum. 2004. PMID: 14872510 - Mediators of joint swelling and damage in rheumatoid arthritis and pristane induced arthritis.
Elson CJ, Thompson SJ, Westacott CI, Bhoola KD. Elson CJ, et al. Autoimmunity. 1992;13(4):327-31. doi: 10.3109/08916939209112342. Autoimmunity. 1992. PMID: 1472643 Review. - Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD).
Verstockt S, Verstockt B, Vermeire S. Verstockt S, et al. Expert Opin Ther Targets. 2019 Nov;23(11):943-954. doi: 10.1080/14728222.2019.1677608. Epub 2019 Oct 15. Expert Opin Ther Targets. 2019. PMID: 31587593 Review.
Cited by
- Role of Oncostatin M in Exercise-Induced Breast Cancer Prevention.
Negrini KA, Lin D, Shah D, Wu H, Wehrung KM, Thompson HJ, Whitcomb T, Sturgeon KM. Negrini KA, et al. Cancers (Basel). 2024 Jul 31;16(15):2716. doi: 10.3390/cancers16152716. Cancers (Basel). 2024. PMID: 39123444 Free PMC article. - Oncostatin M-driven macrophage-fibroblast circuits as a drug target in autoimmune arthritis.
Huynh NC, Ling R, Komagamine M, Shi T, Tsukasaki M, Matsuda K, Okamoto K, Asano T, Muro R, Pluemsakunthai W, Kollias G, Kaneko Y, Takeuchi T, Tanaka S, Komatsu N, Takayanagi H. Huynh NC, et al. Inflamm Regen. 2024 Jul 31;44(1):36. doi: 10.1186/s41232-024-00347-0. Inflamm Regen. 2024. PMID: 39080781 Free PMC article. - Multifaceted oncostatin M: novel roles and therapeutic potential of the oncostatin M signaling in rheumatoid arthritis.
Han L, Yan J, Li T, Lin W, Huang Y, Shen P, Ba X, Huang Y, Qin K, Geng Y, Wang H, Zheng K, Liu Y, Wang Y, Chen Z, Tu S. Han L, et al. Front Immunol. 2023 Nov 1;14:1258765. doi: 10.3389/fimmu.2023.1258765. eCollection 2023. Front Immunol. 2023. PMID: 38022540 Free PMC article. Review. - Role of Interleukin-6 Family Cytokines in Organ Fibrosis.
Chen Y, Zhou J, Xu S, Nie J. Chen Y, et al. Kidney Dis (Basel). 2023 Mar 22;9(4):239-253. doi: 10.1159/000530288. eCollection 2023 Aug. Kidney Dis (Basel). 2023. PMID: 37900004 Free PMC article. Review. - The clinical relevance of OSM in inflammatory diseases: a comprehensive review.
Wolf CL, Pruett C, Lighter D, Jorcyk CL. Wolf CL, et al. Front Immunol. 2023 Sep 29;14:1239732. doi: 10.3389/fimmu.2023.1239732. eCollection 2023. Front Immunol. 2023. PMID: 37841259 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials